The product is a subunit vaccine antigen comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16).
<0.001 EU per 1 μg of the peptide by the LAL method
Investigated for use/treatment in cervical dysplasia/cancer.
Examples of Clinical Use:
Mechanism of action:
TA-CIN is targeted at patients with cervical dysplasia (pre-invasive cervical disease), thus potentially preventing the onset of invasive cervical cancer. The initial product candidate for clinical trials is a genetically engineered fusion of three proteins from HPV 16 known to play a role in the progression of cervical disease.
The HPV16 L2/E6/E7 proteins are key components of the human papillomavirus 16 (HPV16), a common sexually transmitted infection that has been linked to cervical cancer. This particular strain of HPV is responsible for the majority of cervical cancer cases worldwide. The HPV16 L2/E6/E7 proteins play crucial roles in the viral life cycle and the development of HPV-associated diseases.
The discovery of the HPV16 L2/E6/E7 proteins and their relationship to cervical cancer can be attributed to the breakthrough research of Harald zur Hausen and his team in the early 1980s. They identified HPV16 as a high-risk HPV type associated with cervical cancer, leading to the realization that viral infections can be a causative factor in the development of certain cancers.
The gene locus of the HPV16 L2/E6/E7 proteins is found in the DNA of the HPV16 virus, which integrates into the host cell's genome upon infection. The viral genome contains several open reading frames that encode for various proteins, including L2, E6, and E7. These proteins are synthesized during the viral replication cycle and are crucial for HPV infection and the progression of HPV-induced lesions.
HPV16 L2/E6/E7 proteins' function
The HPV16 L2/E6/E7 proteins have distinct functions in the HPV16 life cycle. The L2 protein is involved in viral capsid formation and facilitates viral entry into epithelial cells. The E6 and E7 proteins, on the other hand, play critical roles in the immortalization and transformation of infected cells. E6 targets cellular tumor suppressor protein p53 for degradation, while E7 interacts with the retinoblastoma (Rb) tumor suppressor pathway, leading to cell cycle dysregulation and increased cell proliferation.
HPV16 L2/E6/E7 proteins related signaling pathways
The HPV16 L2/E6/E7 proteins activate several signaling pathways within infected cells, contributing to the viral replication and carcinogenic processes. One important pathway influenced by these proteins is the PI3K/AKT pathway. The activation of this pathway by E6 and E7 promotes cell survival, inhibits apoptosis, and enhances cellular proliferation. Additionally, E6 and E7 can modulate the activity of the MAPK/ERK pathway, which regulates cell growth and differentiation.
HPV16 L2/E6/E7 proteins related diseases
HPV16 L2/E6/E7 proteins are primarily associated with HPV-related diseases, especially cervical cancer. The high-risk HPV types, including HPV16, are known to cause persistent infections that can lead to the development of precancerous lesions and eventually progress to invasive cervical cancer. The E6 and E7 oncoproteins are particularly implicated in the transformation of infected cells and the disruption of cell cycle control mechanisms, contributing to malignant transformation.
The application of HPV16 L2/E6/E7 proteins in medicine is primarily focused on the development of diagnostic tools and therapeutic strategies for HPV-related diseases. The detection of HPV16 E6 and E7 mRNA expression levels can be used as a molecular marker for the early detection of HPV-associated cervical lesions. Additionally, targeting the HPV16 E6 and E7 proteins has become an attractive approach for antiviral and anticancer therapies. Inhibition of E6 and E7 activities aims to restore normal cell cycle control and induce apoptosis in HPV-infected cells.
List of drug candidates related to HPV16 L2/E6/E7 proteins
Several drug candidates have been investigated for their potential in targeting the HPV16 L2/E6/E7 proteins. Small-molecule inhibitors, peptides, and immunotherapies have shown promise in preclinical and clinical studies. For example, the small-molecule inhibitor, E6AP inhibitor, which targets the E6/E6AP interaction, has demonstrated antitumor activity by restoring p53 function in HPV-positive cancers. Additionally, therapeutic vaccines based on HPV16 L2/E6/E7 peptide antigens have been developed to stimulate immune responses against HPV-infected cells.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.